LIXT (Lixte Biotechnology) Net earnings per share growth this year

LIXT (Lixte Biotechnology, Inc.) - company brandmark

EPS YoY volatility demonstrates that the development of Lixte Biotechnology (LIXT) is independent of market conditions, as the fight against cancer remains a priority for medicine. Stable management effectively manages the R&D budget, earning the trust of funds, while the indicator reached the level of 0.00. Production risks are eliminated by outsourcing small molecule synthesis to certified CDMO plants.

Earnings per share growth in current year: Lixte Biotechnology Holdings Inc. (LIXT) for 07/04/2022 - 07/06/2026

Financial and market metric breakdowns for Lixte Biotechnology (LIXT)

- stock quotes and analyst forecast:
Share Price Lixte Biotechnology Holdings Inc.|LIXT - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Lixte Biotechnology, Inc.|LIXT - Total Company Value
- company book value details:
Net Asset Value per Share Lixte Biotechnology|LIXT - Company Book Value|Market Value to Book Value Ratio lixte.com|LIXT - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital Lixte Biotechnology|LIXT - Long-Term Debt to Capital|Short-Term Indebtedness to Equity lixte.com|LIXT - Company Total Debt|Debts to Book Value Lixte Biotechnology, Inc.|LIXT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Lixte Biotechnology|Intermediate Liquidity Ratio lixte.com
- company profitability and valuation multiples indicators:
LIXT - Net Profit|Expected Net Income Lixte Biotechnology|LIXT - P/E Multiple|Projected Price to Earnings Ratio Lixte Biotechnology, Inc.|LIXT - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Lixte Biotechnology, Inc.|LIXT - Operating profit EBITDA|Net earnings per share (EPS TTM) Lixte Biotechnology|LIXT - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months lixte.com|LIXT - Net earnings per share growth this year|Expected net earnings per share growth next year Lixte Biotechnology
Summary company analysis:LIXT Lixte Biotechnology Holdings Inc.
Signature product of Lixte Biotechnology

Lixte Biotechnology investments in the development of innovative cancer inhibitors drive its net profit dynamics. This metric measures the percentage deviation of current earnings per share from the same period last year. A positive trend confirms the effectiveness of the R&D strategy and growth in market capitalization. Sharp spikes signal increased volatility risks. By analyzing the annual EPS change scale, an investor assesses the probability of the asset's future returns.

Key competitors

Earnings per share growth this year INCY|HCM (HUTCHMED Ltd) - Earnings growth in current year|Net earnings per share growth this year Nuvation Corp (NUVB)|Earnings per share growth in current year Day One (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year Inhibrx Biosciences, Inc. INBX|I-Mab Biopharma Co., Ltd. - Earnings per share growth in current year|FENC - Earnings per share growth in current year|Earnings per share growth rate in current year Heron Therapeutics|NVCT: Earnings growth in current year|Net earnings per share change in current year Coherus BioSciences CHRS|Net earnings per share growth this year CRBP|Earnings per share growth rate in current year Cardiff Oncology Corp CRDF|Net earnings per share growth this year BYSI (BeyondSpring Pharma)|BCAB (bioatla.com) - Earnings per share increase in current year|Citius Pharmaceuticals, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CLRB (cellectar.com)|BioLineRx - Earnings growth in current year|Earnings per share increase in current year CANF (Can-Fite BioPharma Ltd)|APRE: Earnings growth in current year|Earnings per share growth rate in current year Kazia Therapeutics Limited (KZIA)|Earnings per share growth in current year Silexion Therapeutics Corp.|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel Pharmaceuticals, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics GTHX|KRON (Kronos Bio Corporation) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year oncternal.com|Portage Biotech (PRTG) - Earnings per share growth in current year